Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. - Wikidata - wikimedia - TriplyDB

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.

http://www.wikidata.org/entity/Q35673081

about

Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies.Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.The role of incretin therapy at different stages of diabetes.Evolution of exenatide as a diabetes therapeutic.A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice.Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.What are the important subsets of gastroparesis?Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.Managing diabetes in patients with diabetes of long duration.GLP-1 receptor agonists: effects on cardiovascular risk reduction.Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions.Crossover design and its application in late-phase diabetes studies.Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research.Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?Incretin manipulation in diabetes management.A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sita A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes.Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.

P2860

Q26770832-A727FE2D-57B0-4D19-8F05-1D100DADF397 Q26992979-2D7A6AAC-0F69-4AB9-A106-F8AD92E5807C Q33999894-BB908FE0-EB24-4B6F-8DF2-296A979662F7 Q34496741-F8E0752E-7360-4902-A43A-3E2752232C72 Q34547492-3FEF4512-0329-4C2A-8CF4-CF226C445A90 Q34665186-559DD70B-C0F5-4B80-9DA4-EB6AFDC91E23 Q35760288-5E70DE63-A105-4428-8246-0C51067EDF2C Q36877205-2161DAD5-9FF1-4745-A7DE-690B1EE1B407 Q36941729-1E0950B7-C19C-4CFE-8573-A00FAFF9C5AC Q36972891-5D5F65CC-B095-4322-897B-E47A65FD88F8 Q37204670-309652EB-8D2F-46F3-BD7D-B9295D4E4862 Q37635255-F9FECD71-C39A-46E5-9095-7DA3CC6E9F8F Q37653125-1EF5F443-F35E-4BFA-9561-D4A8F54E8DF2 Q37995760-700F0A4E-5261-4483-9708-506C18953385 Q38015776-2C0DCC4D-69FB-42AD-AC5E-32501FA77DC6 Q38122396-5320AE83-564D-4D95-858F-5D6103913F2D Q38179267-391C89D4-AE7A-48E0-89DE-A5BE0D2583A9 Q38264456-82633348-34C5-4467-8116-06C44A26E3E3 Q38813734-BD09E5F4-A58F-4055-B4CF-33EFE330B75A Q38824034-E19F2DE8-4F28-4FE8-917C-64B96EBFF993 Q39157526-7BBF482E-C415-4906-96E4-8047C9A60558 Q41906284-0165187D-9BEA-4548-BC67-F5D3BC34A22C Q43829451-7FEAB181-83E2-422F-ACF2-FE5EDF4AF555 Q44310507-918AB1B8-99E2-4FE1-8FAA-BDDC8D66BA61 Q46869132-95BB63B1-5740-4D3E-9387-E60660DE1165 Q47951604-1939AE9D-7948-4FC7-9A83-8C37F273A76F Q51357618-DF443A01-2619-447C-B4AC-934C36DCFFC6

P2860

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.

http://www.wikidata.org/entity/Q35673081

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Effects of exenatide twice dai ...... double-blind, crossover study.

@ast

Effects of exenatide twice dai ...... double-blind, crossover study.

@en

type

label

Effects of exenatide twice dai ...... double-blind, crossover study.

@ast

Effects of exenatide twice dai ...... double-blind, crossover study.

@en

prefLabel

Effects of exenatide twice dai ...... double-blind, crossover study.

@ast

Effects of exenatide twice dai ...... double-blind, crossover study.

@en

P1433

Q35673081-8BCDE02F-56CF-4017-ABA2-65990931CF00

P1476

Q35673081-731A2C4B-D29B-48B3-8E28-0D87EDBAFCEC

P2093

Q35673081-436F1365-DC7A-4075-A07D-2C717F87BA72

Q35673081-6523C711-94E5-4368-8567-1A26154CC7CE

Q35673081-66DC4D8D-CAE8-49C5-BEF5-1EE33A186740

Q35673081-A00FC8CE-8A8E-4FCB-96C8-894073F663DF

Q35673081-BECC3462-99E8-4D25-BF53-FDFAA9BD2877

P2860

Q35673081-0487493B-32C7-45C3-AA52-195796734EA0

Q35673081-1E550B14-5699-4C52-8048-365C246158CB

Q35673081-2B484856-A6F0-46D2-AEF7-1F9D618A5E35

Q35673081-3B659F2E-6073-412A-8DE9-2A4692874F86

Q35673081-3DC7ABFD-5201-4A6D-8FBB-739BCBE2AD84

Q35673081-47345296-E8D2-4590-A55E-BA2F41EC53F3

Q35673081-5E3EB6D1-6537-4858-B977-004F577AD534

Q35673081-6DCD4F03-8548-41F7-B961-19A520D58015

Q35673081-73B214D4-5917-4989-A505-C39C13666DE9

Q35673081-772D9EB0-D9BB-4408-8F2C-0362F4141ECD

P304

Q35673081-83904B8E-EDBD-4BB0-941E-44E5CD4327AF

P31

Q35673081-EF75AD43-F048-4F25-8288-3AB366D7C5F5

P356

Q35673081-3D5B7187-EA3E-45B2-8796-449131F0A13D

P433

Q35673081-5CF43DCA-7DAC-4910-8947-0294B2489211

P478

Q35673081-656B5F9E-80C6-4CAB-9AB1-D38E9B715FDE

P577

Q35673081-A73FC552-B1B3-4094-BEFC-4496616854AB

P5875

Q35673081-11214E57-5466-4924-8FB8-41630B2CFC61

P698

Q35673081-B1B44E6C-B1DA-47EE-AD75-D28483134068

P932

Q35673081-7E785E30-5A32-4F20-B533-220499E18F01

P356

J.1463-1326.2011.01428.X

P1433

Diabetes, Obesity and Metabolism

P1476

Effects of exenatide twice dai ...... double-blind, crossover study.

@en

P2093

A L Gray

http://www.w3.org/2001/XMLSchema#string

C R Heilmann

http://www.w3.org/2001/XMLSchema#string

J H Holcombe

http://www.w3.org/2001/XMLSchema#string

J K Berg

http://www.w3.org/2001/XMLSchema#string

S K Shenouda

http://www.w3.org/2001/XMLSchema#string

P2860

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Use and abuse of HOMA modeling

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.

Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

The biology of incretin hormones.

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.

Impact of lack of suppression of glucagon on glucose tolerance in humans.

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.

P304

982-989

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1463-1326.2011.01428.X

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51168225

http://www.w3.org/2001/XMLSchema#string

P698

21615670

http://www.w3.org/2001/XMLSchema#string

P932

3258427

http://www.w3.org/2001/XMLSchema#string